
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

The FDA has approved the imaging product TLX591-CDx as a radioactive diagnostic agent for PET of prostate-specific membrane antigen positive lesions in patients with prostate cancer who have suspected metastasis who are candidates for initial definitive therapy, and in those with suspected recurrence based on elevated serum prostate-specific antigen level.

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.

The FDA has awarded 510K clearance to the Exablate Prostate system for the treatment of prostate cancer.

The addition of darolutamide to docetaxel and androgen deprivation therapy resulted in a significant improvement in overall survival compared with docetaxel/ADT alone in patients with metastatic hormone-sensitive prostate cancer, meeting the primary end point of the phase 3 ARASENS trial.

Patients with locally advanced or metastatic hormone-sensitive prostate cancer who received docetaxel and abiraterone acetate plus prednisone or prednisolone and standard of care androgen deprivation therapy had superior patient-reported quality of life compared with patients who received docetaxel plus ADT, although the improvement narrowly missed the predefined value for clinical significance.

Jeff M. Michalski, MD, MBA, FASTRO, shares his presidential goals for ASTRO, the success of the hybrid 2021 ASTRO Annual Meeting, and remaining questions in radiation oncology that research efforts are poised to address.

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

The use of androgen deprivation therapy and prolongation of adjuvant ADT to at least 18 months in conjunction with definitive radiotherapy provides clinically meaningful benefit for patients with localized prostate cancer, irrespective of radiation dose.

Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen screening from age 40 to identify men with clinically significant prostate cancer.

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Investigators have made great strides in the development of radiopharmaceuticals for prostate cancer diagnostics, culminating in recent FDA approvals for the first prostate-specific membrane antigen–targeted radioligands, gallium 68–PSMA-11 and piflufolastat F 18, for the detection of disease recurrence and metastatic lesions.

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.
























































